Market Research Hub (MRH) has actively included a new research study titled “Global Asset Purchase Partnering” Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2019 to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until 2019. In addition, a deep analysis of the competitive landscape, including prime market players is also enclosed in this report.
Get Sample Copy of This Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2222643
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2014-2019 report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.
The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets.
The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets.
Companies may seek to dispose of an asset simply because it is surplus to requirements. Or it may seek to dispose of assets in order to raise funds to invest in others parts of its business. Or it may be due to a regulatory requirement to dispose of certain business or product assets as a result of a pending business merger in order to meet competition regulations.
The report provides access to asset purchase deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
The report focuses on four primary types of asset available for purchase:
Business assets – the most common asset exchanging hands. Business assets are in the form of a business unit or subsidiary of a parent company. Common assets include territorial businesses or non-core businesses such as an OTC or diagnostics business, separate from the core business operations
Product assets – in the form of marketed product, clinical phase development compound, or drug delivery-compound combination. These assets are commonly available as a result of a merger or change in direction of the selling company. The buyer acquires the asset for global or territorial exploitation. It is often the case that the acquiring company is normally a competitor to the seller, but in this situation the trade is of mutual benefit
Royalty assets – where a specialist investment company acquires the rights to future royalty payments in return for payment of a lump sum payment to the licensor for the product
Technology asset – where a buyer is acquiring a technology platform, research program, patent portfolio or other intellectual property asset. The acquisition is often due to the technology being surplus to a sellers interests, but may also be as a consequence of a sale of assets in advance of the seller entering liquidation
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 1,000 asset purchase deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Chapter 1 Introduction
Chapter 2 Trends in Asset Purchase dealmaking
2.2. Types of assets purchased
2.3. Trends in Asset Purchase deals since 2014
2.3.1. Asset Purchase dealmaking by year since 2014
2.3.2. Asset Purchase dealmaking by phase of development since 2014
2.3.3. Asset Purchase dealmaking by industry sector since 2014
2.3.4. Asset Purchase dealmaking by therapy area since 2014
2.3.5. Asset Purchase dealmaking by technology type since 2014
2.3.6. Asset Purchase dealmaking by most active company since 2014
2.4. Reasons for entering into asset purchase partnering deals
2.4.1. Business assets
2.4.2. Product assets
2.4.3. Royalty assets
2.4.4. Technology assets
2.5 The emergence of royalty asset purchase deals
2.5.1. Primary players in royalty asset purchase deals
2.5.3. The future of royalty asset purchase deals
2.6. The role of IP auction houses in asset purchase deals
2.6.1. Leading IP auction companies
2.7. The future of asset purchase agreements
Chapter 3 Overview of Asset Purchase deal structure
3.2. Asset purchase agreement structure
3.3. Example asset purchase agreements
3.3.1. Case study 1: Product asset: QLT Valeant Pharmaceuticals
3.3.2. Case study 2: Business asset: Merck and Co Bayer
3.4. Anatomy of a royalty asset purchase agreement
3.5. Example royalty asset purchase agreements
3.5.1. Case study 3: Royalty asset: BioTime Acquisition Corporation Geron Corporation
Chapter 4 Leading Asset Purchase deals
4.2. Top Asset Purchase deals by value
Chapter 5 Top 50 most active Asset Purchase dealmakers
5.2. Top 50 most active Asset Purchase dealmakers
Chapter 6 Asset Purchase deals including contracts directory
6.2. Asset Purchase deals with contracts since 2014
Enquire about this Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2222643
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
90 State Street,
Albany, NY 12207,
Toll Free: 800-998-4852 (US-Canada)
Email: [email protected]
Read Industry News at: https://www.industrynewsanalysis.com/